中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2011年
2期
142-146
,共5页
朱慧%周宗玫%冯勤付%欧广飞%梁军%张湘茹%张红星%陈东福%肖泽芬%王绿化
硃慧%週宗玫%馮勤付%歐廣飛%樑軍%張湘茹%張紅星%陳東福%肖澤芬%王綠化
주혜%주종매%풍근부%구엄비%량군%장상여%장홍성%진동복%초택분%왕녹화
癌,小细胞肺%广泛期%放射疗法%预后
癌,小細胞肺%廣汎期%放射療法%預後
암,소세포폐%엄범기%방사요법%예후
Neoplasms,small cell lung%Extensive stage%Radiotherapy%Prognosis
目的 探讨胸部放疗在广泛期小细胞肺癌中的应用价值及对患者预后的影响.方法 回顾性分析154例广泛期小细胞肺癌患者的临床资料,化放疗组89例,化疗组65例.放疗采用常规分割1.8～2.0 Gy/次,1次/d,总剂量为40～60 Gy,化疗采用EP方案(顺铂+依托泊甙)、CE方案(卡铂+依托泊甙)或者CAO方案(环磷酰胺+阿霉素+长春新碱).结果 全组中位生存时间为13.7个月,2年和5年生存率分别为27.9%和8.1%,其中化放疗组分别为17.2个月、36.0%和10.1%,化疗组分别为9.3个月、16.9%和4.6%,两组生存率差异有统计学意义(P=0.001).全组中位无进展生存时间为8.0个月,2年和5年无进展生存率分别为13.6%和8.2%,其中化放疗组分别为10.0个月、17.4%和10.5%,化疗组分别为6.2个月、9.8%和4.9%.两组无进展生存率差异有统计学意义(P＜0.001).化放疗组胸内复发率为29.6%(21/89),化疗组胸内复发率为70.0%(42/65),差异有统计学意义(P=0.000).结论 胸部放疗能降低广泛期小细胞肺癌局部失败的发生率,延长患者的总生存时间和无进展生存时间.
目的 探討胸部放療在廣汎期小細胞肺癌中的應用價值及對患者預後的影響.方法 迴顧性分析154例廣汎期小細胞肺癌患者的臨床資料,化放療組89例,化療組65例.放療採用常規分割1.8～2.0 Gy/次,1次/d,總劑量為40～60 Gy,化療採用EP方案(順鉑+依託泊甙)、CE方案(卡鉑+依託泊甙)或者CAO方案(環燐酰胺+阿黴素+長春新堿).結果 全組中位生存時間為13.7箇月,2年和5年生存率分彆為27.9%和8.1%,其中化放療組分彆為17.2箇月、36.0%和10.1%,化療組分彆為9.3箇月、16.9%和4.6%,兩組生存率差異有統計學意義(P=0.001).全組中位無進展生存時間為8.0箇月,2年和5年無進展生存率分彆為13.6%和8.2%,其中化放療組分彆為10.0箇月、17.4%和10.5%,化療組分彆為6.2箇月、9.8%和4.9%.兩組無進展生存率差異有統計學意義(P＜0.001).化放療組胸內複髮率為29.6%(21/89),化療組胸內複髮率為70.0%(42/65),差異有統計學意義(P=0.000).結論 胸部放療能降低廣汎期小細胞肺癌跼部失敗的髮生率,延長患者的總生存時間和無進展生存時間.
목적 탐토흉부방료재엄범기소세포폐암중적응용개치급대환자예후적영향.방법 회고성분석154례엄범기소세포폐암환자적림상자료,화방료조89례,화료조65례.방료채용상규분할1.8～2.0 Gy/차,1차/d,총제량위40～60 Gy,화료채용EP방안(순박+의탁박대)、CE방안(잡박+의탁박대)혹자CAO방안(배린선알+아매소+장춘신감).결과 전조중위생존시간위13.7개월,2년화5년생존솔분별위27.9%화8.1%,기중화방료조분별위17.2개월、36.0%화10.1%,화료조분별위9.3개월、16.9%화4.6%,량조생존솔차이유통계학의의(P=0.001).전조중위무진전생존시간위8.0개월,2년화5년무진전생존솔분별위13.6%화8.2%,기중화방료조분별위10.0개월、17.4%화10.5%,화료조분별위6.2개월、9.8%화4.9%.량조무진전생존솔차이유통계학의의(P＜0.001).화방료조흉내복발솔위29.6%(21/89),화료조흉내복발솔위70.0%(42/65),차이유통계학의의(P=0.000).결론 흉부방료능강저엄범기소세포폐암국부실패적발생솔,연장환자적총생존시간화무진전생존시간.
Objective To evaluate the effect of thoracic radiation therapy(TRT) on patients with extensive stage small-cell lung cancer(SCLC). Methods One hundred and fifty-four patients with extensive stage SCLC treated in our department between January 2003 and December 2006 were enrolled in this study.Eighty nine patients received chemotherapy and thoracic radiation therapy(ChT/TRT),and 65 patients were treated with chemotherapy alone(ChT without TRT).The chemotherapy was CE(carboplatin and etoposide),PE(cisplatin and etoposide) or CAO(CTX,ADM and VCR) regimens.The total dose of thoracic irradiation was 40-60 Gy with 1.8-2.0 Gy per fraction. Results For the whole group,the median survival time(MST) was 13.7 months,the 2-year and 5-year overall survival rates were 27.9% and 8.1%,respectively.The MST,overall survival rates at 2 years and 5 years in the ChT/TRT group and ChT without TRT group were 17.2 months,36.0%,10.1% and 9.3 months,16.9%,4.6%,respectively(P =0.001).The median progression-free survival(PFS) for all patients was 8.0 months,the 2-year and 5-year PFS were 13.6% and 8.2%,respectively.The median PFS,2-year and 5-year PFS in the ChT/TRT group and ChT without TRT group were 10.0 months,17.4%,10.5% and 6.2 months,9.8%,4.9%,respectively(P ＜0.001).The incidence of intra-thoracic local failure was 29.6% in the ChT/TRT group and 70.0% in the ChT/without TRT group(P = 0.000). Conclusions Chemotherapy plus thoracic radiation therapy can improve the overall survival,progress free survival and reduce local regional failure rate in patients with extensive stage SCLC compared with that by chemotherapy alone.
